ATE490788T1 - Antivirale phosphonate analoge - Google Patents

Antivirale phosphonate analoge

Info

Publication number
ATE490788T1
ATE490788T1 AT04750807T AT04750807T ATE490788T1 AT E490788 T1 ATE490788 T1 AT E490788T1 AT 04750807 T AT04750807 T AT 04750807T AT 04750807 T AT04750807 T AT 04750807T AT E490788 T1 ATE490788 T1 AT E490788T1
Authority
AT
Austria
Prior art keywords
compounds
phosphonate analogue
antiviral phosphonate
antiviral
analogue
Prior art date
Application number
AT04750807T
Other languages
English (en)
Inventor
Constantine Boojamra
Carina Cannizzaro
James Chen
Xiaowu Chen
Aesop Cho
Lee Chong
Maria Fardis
Haolun Jin
Ralph Hirschmann
Alan Huang
Choung Kim
Thorsten Kirschberg
Christopher Lee
William Lee
Richard Mackman
David Markevitch
Vidya Prasad
Hyung-Jung Pyun
Adrian Ray
Rosemarie Sherlock
Sundaramoorthi Swaminathan
Will Watkins
Jennifer Zhang
David Oare
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE490788T1 publication Critical patent/ATE490788T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT04750807T 2003-04-25 2004-04-26 Antivirale phosphonate analoge ATE490788T1 (de)

Applications Claiming Priority (92)

Application Number Priority Date Filing Date Title
US46528903P 2003-04-25 2003-04-25
US46560803P 2003-04-25 2003-04-25
US46537703P 2003-04-25 2003-04-25
US46569803P 2003-04-25 2003-04-25
US46554803P 2003-04-25 2003-04-25
US46546903P 2003-04-25 2003-04-25
US46555403P 2003-04-25 2003-04-25
US46574203P 2003-04-25 2003-04-25
US46561003P 2003-04-25 2003-04-25
US46540803P 2003-04-25 2003-04-25
US46555003P 2003-04-25 2003-04-25
US46563303P 2003-04-25 2003-04-25
US46563003P 2003-04-25 2003-04-25
US46559103P 2003-04-25 2003-04-25
US46566703P 2003-04-25 2003-04-25
US46564703P 2003-04-25 2003-04-25
US46560203P 2003-04-25 2003-04-25
US46534703P 2003-04-25 2003-04-25
US46556103P 2003-04-25 2003-04-25
US46582103P 2003-04-25 2003-04-25
US46560003P 2003-04-25 2003-04-25
US46555303P 2003-04-25 2003-04-25
US46546303P 2003-04-25 2003-04-25
US46563403P 2003-04-25 2003-04-25
US46555903P 2003-04-25 2003-04-25
US46564903P 2003-04-25 2003-04-25
US46568703P 2003-04-25 2003-04-25
US46584403P 2003-04-25 2003-04-25
US46559803P 2003-04-25 2003-04-25
US46568403P 2003-04-25 2003-04-25
US46553703P 2003-04-25 2003-04-25
US46554403P 2003-04-25 2003-04-25
US46547803P 2003-04-25 2003-04-25
US46540003P 2003-04-25 2003-04-25
US46569603P 2003-04-25 2003-04-25
US46532203P 2003-04-25 2003-04-25
US46558403P 2003-04-25 2003-04-25
US46572003P 2003-04-25 2003-04-25
US46558703P 2003-04-25 2003-04-25
US46569003P 2003-04-25 2003-04-25
US46575903P 2003-04-25 2003-04-25
US49079903P 2003-07-29 2003-07-29
US49538803P 2003-08-15 2003-08-15
US49534403P 2003-08-15 2003-08-15
US49527703P 2003-08-15 2003-08-15
US49577203P 2003-08-15 2003-08-15
US49543003P 2003-08-15 2003-08-15
US49527503P 2003-08-15 2003-08-15
US49542503P 2003-08-15 2003-08-15
US49576303P 2003-08-15 2003-08-15
US49534103P 2003-08-15 2003-08-15
US49561603P 2003-08-15 2003-08-15
US49531703P 2003-08-15 2003-08-15
US49567103P 2003-08-15 2003-08-15
US49548503P 2003-08-15 2003-08-15
US49563103P 2003-08-15 2003-08-15
US49576003P 2003-08-15 2003-08-15
US49534503P 2003-08-15 2003-08-15
US49596403P 2003-08-15 2003-08-15
US49534303P 2003-08-15 2003-08-15
US49563303P 2003-08-15 2003-08-15
US49545303P 2003-08-15 2003-08-15
US49539303P 2003-08-15 2003-08-15
US49527303P 2003-08-15 2003-08-15
US49563003P 2003-08-15 2003-08-15
US49556403P 2003-08-15 2003-08-15
US49568703P 2003-08-15 2003-08-15
US49568403P 2003-08-15 2003-08-15
US49533403P 2003-08-15 2003-08-15
US49580503P 2003-08-15 2003-08-15
US49539203P 2003-08-15 2003-08-15
US49527803P 2003-08-15 2003-08-15
US49569603P 2003-08-15 2003-08-15
US49553903P 2003-08-15 2003-08-15
US49549103P 2003-08-15 2003-08-15
US49549003P 2003-08-15 2003-08-15
US49563203P 2003-08-15 2003-08-15
US49559203P 2003-08-15 2003-08-15
US49560003P 2003-08-15 2003-08-15
US49560203P 2003-08-15 2003-08-15
US49534903P 2003-08-15 2003-08-15
US49534203P 2003-08-15 2003-08-15
US49538703P 2003-08-15 2003-08-15
US51024503P 2003-10-10 2003-10-10
US51425803P 2003-10-24 2003-10-24
US51394803P 2003-10-24 2003-10-24
US51420203P 2003-10-24 2003-10-24
US51526603P 2003-10-29 2003-10-29
US51947603P 2003-11-12 2003-11-12
US52434003P 2003-11-20 2003-11-20
US53259103P 2003-12-23 2003-12-23
PCT/US2004/013063 WO2004096286A2 (en) 2003-04-25 2004-04-26 Antiviral phosphonate analogs

Publications (1)

Publication Number Publication Date
ATE490788T1 true ATE490788T1 (de) 2010-12-15

Family

ID=33425965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750807T ATE490788T1 (de) 2003-04-25 2004-04-26 Antivirale phosphonate analoge

Country Status (17)

Country Link
US (5) US7429565B2 (de)
EP (2) EP2359833A1 (de)
JP (2) JP5069463B2 (de)
AT (1) ATE490788T1 (de)
AU (1) AU2004233898B2 (de)
CA (1) CA2523083C (de)
CY (1) CY1118836T1 (de)
DK (1) DK1628685T3 (de)
EA (1) EA014685B1 (de)
IL (1) IL170894A (de)
MX (1) MXPA05011297A (de)
NO (1) NO338306B1 (de)
NZ (1) NZ542342A (de)
PL (1) PL1628685T3 (de)
PT (1) PT1628685E (de)
SG (1) SG182849A1 (de)
WO (1) WO2004096286A2 (de)

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2011218664B2 (en) * 2004-07-27 2014-08-21 Gilead Sciences, Inc. Antiviral compounds
PL216369B1 (pl) * 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
WO2006037090A2 (en) * 2004-09-28 2006-04-06 Purdue Research Foundation Drug-phosphate conjugates as prodrugs
EP1831235B1 (de) 2004-12-16 2013-02-20 The Regents of The University of California Arzneimittel für die lungen
CA2602533A1 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
ITRM20050391A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
BRPI0617274A2 (pt) * 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008100447A2 (en) * 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2265626B1 (de) 2008-03-18 2019-05-15 LCB Pharma Inc Nukleotid-analoga mit quaternären stereogenen kohlenstoffzentren und verwendungsverfahren
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR072428A1 (es) * 2008-07-01 2010-08-25 Medivir Ab Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376515A1 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
KR101150254B1 (ko) 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8680071B2 (en) 2010-04-01 2014-03-25 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2691409B1 (de) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
US8987437B2 (en) 2011-05-19 2015-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-HIV Agents
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013019874A1 (en) * 2011-08-01 2013-02-07 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
ES2650464T3 (es) * 2011-10-14 2018-01-18 Aktsionernoe Obshcestvo "Proizvodstvenno-Kommercheskaya Assotsiatsiya AZT" Sales de ésteres del ácido carbamoil-fosfónico que actúan como inhibidores selectivos de la producción del virus de la inmunodeficiencia humana VIH-1
EP2768838A1 (de) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
US8859098B2 (en) * 2012-05-18 2014-10-14 Lord Corporation Acrylic adhesion promoters
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
GEP20176800B (en) 2012-05-22 2018-01-10 Idenix Pharmaceuticals Llk D-amino acid compounds for liver disease
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
WO2014033617A1 (en) 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
EP2900682A1 (de) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Ester und malonate aus sate-prodrugs
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970358B1 (de) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-deoxy-nukleoside zur behandlung von hcv
KR101857337B1 (ko) * 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
CN107056838A (zh) 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (de) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
NO2717902T3 (de) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
WO2016068220A1 (ja) 2014-10-29 2016-05-06 学校法人東京理科大学 ユーシェアリライド類の製造方法
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのイソキノリン化合物
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016134058A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
ES2797900T3 (es) 2015-09-30 2020-12-04 Gilead Sciences Inc Compuestos y combinaciones para el tratamiento del VIH
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
US10390758B2 (en) * 2016-03-24 2019-08-27 Samsung Electronics Co., Ltd. Method and apparatus for triage and subsequent escalation based on biosignals or biometrics
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
SI3347352T1 (sl) 2016-08-19 2019-08-30 Gilead Sciences, Inc. Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
EP3506909B1 (de) * 2016-09-02 2022-06-29 Dicerna Pharmaceuticals, Inc. 4'-phosphat-analoga und oligonukleotide damit
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018064080A1 (en) 2016-09-28 2018-04-05 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
EP3532478B1 (de) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form von darunavir freie base
TWI868958B (zh) 2017-01-31 2025-01-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
JP7212900B2 (ja) 2017-04-17 2023-01-26 株式会社ナールスコーポレーション 光学活性な２－アミノ－ホスホノアルカン酸、光学活性な２－アミノ－ホスホノアルカン酸塩、及びこれらの水和物
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
WO2018230479A1 (ja) * 2017-06-13 2018-12-20 大原薬品工業株式会社 ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US10688112B2 (en) 2017-07-13 2020-06-23 Emory University Lipid disulfide prodrugs and uses related thereto
EP3661937B1 (de) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019084020A1 (en) 2017-10-24 2019-05-02 Gilead Sciences, Inc. METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3728283B1 (de) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclische dinukleotide mit phosphonatbindung zur aktivierung des sting-adapterproteins
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
EP3773753A4 (de) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Behandlung von hcv-infizierten patienten mit zirrhose
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
CR20200653A (es) 2018-07-03 2021-02-11 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
EP3860591A4 (de) * 2018-10-04 2022-06-01 Octagon Therapeutics Inc. Präaktivierte nucleosid-impdh-inhibitoren als antiinfektiöse arzneimittel
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
CN109761984B (zh) * 2019-02-27 2020-07-07 河南师范大学 不对称氢转移合成手性五元碳环嘌呤核苷的方法
EP3935065A1 (de) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclisches dinukleotid-analogon mit einem cyclopentanyl-modifizierten nukleotid als sting-modulator
EP3934757B1 (de) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-zyklische dinukleotide und prodrugs davon
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4017499A4 (de) 2019-08-22 2024-01-10 Emory University Nukleosid-prodrugs und damit zusammenhängende verwendungen
TW202519228A (zh) 2019-11-26 2025-05-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
EP4132651B1 (de) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalationsformulierungen von 1'-cyansubstituierten carbanukleosidanaloga
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (de) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyanonukleosidanaloga und verwendungen davon
EP4172157B1 (de) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Capsid-inhibitoren zur behandlung von hiv
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4660325A3 (de) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Verfahren zur identifizierung von auf eine therapie mit gp120-cd4-bindungsstelle gerichteten antikörpern ansprechenden hiv-patienten
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20250326779A1 (en) 2024-04-03 2025-10-23 Gilead Sciences, Inc. Anti-hiv compounds
WO2025240608A1 (en) * 2024-05-14 2025-11-20 Rome Therapeutics, Inc. Cyclo-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4649041A (en) 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5455339A (en) 1986-05-01 1995-10-03 University Of Georgia Research Foundation, Inc. Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
FR2611203B1 (fr) 1987-02-20 1989-06-09 Sturtz Georges Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5466793A (en) 1988-03-01 1995-11-14 Ajinomoto Co., Inc. Process for preparing 2', 3'- dideoxyinosine
ZA894534B (en) 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
CA2001715C (en) * 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
JP2722673B2 (ja) * 1989-05-31 1998-03-04 住友化学工業株式会社 光学活性なアシルビフェニル誘導体の製造法
DE4003574A1 (de) 1990-02-07 1991-08-08 Bayer Ag Neue dipeptide, verfahren zu ihrer herstellung und ihre verwendung als renininhibitoren in arzneimitteln
JPH0690744B2 (ja) 1990-05-24 1994-11-14 四国旅客鉄道株式会社 乗車券類発売機
EP0533833B1 (de) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorylierte prodrugs
DE69116750T2 (de) 1990-07-04 1996-11-14 Merrell Dow Pharma 9-Purinyl-Phosphonsäurederivate
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
EP0468119A1 (de) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Neue Carbocyclische Analoge einiger Nukleoside
US6087482A (en) 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
DE4111730A1 (de) 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0531597A1 (de) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Ungesättigte azyklische Phosphonsäure Purinderivats und Pyrimidinderivate
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
DE4138584A1 (de) * 1991-11-23 1993-05-27 Hoechst Ag Carbocyclische phosphonat-nucleotidanaloge, deren herstellung und verwendung
GB9126144D0 (en) 1991-12-10 1992-02-12 British Bio Technology Compounds
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CA2126601A1 (en) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
JPH09500120A (ja) 1993-07-14 1997-01-07 チバ−ガイギー アクチェンゲゼルシャフト 環式ヒドラジン化合物
AU673775B2 (en) * 1993-08-24 1996-11-21 Great Lakes Chemical Corporation Ophthalmic lenses
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5493030A (en) 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5854227A (en) 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
KR100387157B1 (ko) 1994-09-26 2003-09-29 시오노기세이야쿠가부시키가이샤 이미다졸유도체
JP2002515849A (ja) 1994-11-04 2002-05-28 ギリアード サイエンシーズ，インコーポレイテッド Ｈｉｖプロテアーゼを阻害および検出するチエパン化合物
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ES2097703B1 (es) 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6299496A (en) 1995-06-29 1997-01-30 Novo Nordisk A/S Novel substituted azabicyclic compounds
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
EP0852233A4 (de) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd Cyclosporin-phosphat-derivate und medizinische zusammensetzungen
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
RU2106353C1 (ru) 1996-03-19 1998-03-10 Корпорация "С энд Ти Сайенс энд Текнолоджи Инк." Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2
US5874577A (en) 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
ES2186911T3 (es) 1996-08-13 2003-05-16 Mitsubishi Chem Corp Compuestos nucleotidico de fosfonato.
JP2002514183A (ja) 1996-09-17 2002-05-14 スーパージェン・インコーポレーテッド リン脂質薬剤誘導体
KR100560182B1 (ko) 1996-10-09 2006-03-13 파마셋 인코포레이티드 비스포스포네이트 화합물
ATE261944T1 (de) 1996-12-26 2004-04-15 Shionogi & Co Verfahren zur herstellung von carbamoylsubstituierten imidazolderivaten
WO1999029702A2 (en) 1997-12-10 1999-06-17 The Government Of The United States Of America Reppresented By The Secretary, Department Of Health And Human Services METHOD FOR SYNTHESIZING 9-(2,3-DIDEOXY-2-FLUORO-β-D-THREO-PENTOFURANOSYL)ADENINE (β-FddA)
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
AU4125099A (en) 1998-06-01 1999-12-20 S & T Science And Technology Inc. Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
HK1043796B (en) 1999-03-05 2007-02-23 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrugs
DE19912636A1 (de) * 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6258831B1 (en) 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19927689A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DK1196414T3 (da) 1999-06-25 2003-11-24 Vertex Pharma Prolægemiddel af carbamathæmmer for IMPDH
US6581606B2 (en) 1999-07-06 2003-06-24 The Rx Files Corporation Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response
EP2269654A3 (de) 1999-08-24 2011-04-13 Cellgate Inc. Verbesserung des Verabreichung von Arzneimitteln durch und in epitheliale Gewebe rch Verwendung von Oligoarginin-Gruppen
GB9920872D0 (en) 1999-09-04 1999-11-10 Glaxo Group Ltd Benzophenones as inhibitors of reverse transcriptase
IL131887A0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
MXPA02006156A (es) 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
EP1242431A1 (de) 1999-12-22 2002-09-25 Merck Frosst Canada & Co. Aromatische phosphonate als protein tyrosin phosphatase 1b (ptp-1b) inhibitoren
KR20020093824A (ko) * 2000-02-29 2002-12-16 미쯔비시 웰 파마 가부시키가이샤 포스포네이트 뉴클레오티드 화합물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
HUP0301713A3 (en) 2000-06-13 2005-04-28 Shionogi & Co Pharmaceutical compositions containing propenone derivatives and their use
FR2810322B1 (fr) 2000-06-14 2006-11-10 Pasteur Institut PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6617310B2 (en) 2000-07-19 2003-09-09 Bristol-Myers Squibb Pharma Company Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines
OA12393A (en) 2000-07-21 2006-04-18 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same.
US6420586B1 (en) 2000-08-15 2002-07-16 University Of Kansas Amino acid-derived cyclic phosphonamides and methods of synthesizing the same
ATE343384T1 (de) 2000-09-08 2006-11-15 Zeria Pharm Co Ltd Pharmazeutische zusammensetzungen enthaltend aminothiazole derivate zur behandlung von motorischen störungen des dickdarms
RU2188203C2 (ru) 2000-10-05 2002-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
MXPA03005923A (es) 2000-12-28 2004-01-26 Kissei Pharmaceuticals Co Ltd Derivados de glupopiranosiloxipirazol y su uso en medicinas.
DZ3487A1 (fr) * 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
WO2002060893A1 (en) 2001-01-31 2002-08-08 Warner-Lambert Company Llc Method for carbamoylating alcohols
DE60221642T3 (de) 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
EP1262458B1 (de) 2001-05-31 2008-03-05 Sumitomo Chemical Company, Limited Verfahren zur Herstellung eines aktivierten Aluminiumoxid-Formkörpers
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
KR20020097384A (ko) 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
EP2305808B1 (de) 2001-06-20 2016-03-02 Nuevolution A/S Matrizenabhängige Moleküle und Verfahren zur Verwendung derartiger Moleküle
DE50212935D1 (de) * 2001-07-20 2008-12-04 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
DE60232981D1 (de) 2001-08-17 2009-08-27 Sankyo Agro Co Ltd 3-phenoxy-4-pyridazinolderivat und dieses enthaltende herbizide zusammensetzung
JP2005508924A (ja) * 2001-08-30 2005-04-07 三菱ウェルファーマ株式会社 抗ウイルス剤
MXPA04003192A (es) 2001-11-29 2004-07-27 Pfizer Prod Inc Sales de acido succinico de 5, 7, 14-triazatetraciclo ?10.3.1.02,11.04,9? -hexadeca-2(11), 3, 5, 7, 9-pentaeno y composiciones farmacetucias de las mismas.
WO2003050129A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
HRP20040530A2 (en) 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
UA77033C2 (uk) 2001-12-21 2006-10-16 Mgi Gp Inc Спосіб отримання водорозчинних фосфонооксиметильних похідних спирту та фенолу
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
JP2005530689A (ja) 2002-02-08 2005-10-13 コンフォーマ・セラピューティクス・コーポレイション 改良された薬理学的および生物学的特性を有するアンサマイシン
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003216523A1 (en) 2002-03-18 2003-10-08 Mitsubishi Pharma Corporation Treatment of pre-core hepatitis b virus mutant infections
JP2005525398A (ja) 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
WO2003090691A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US6872827B2 (en) 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
EP1540937A4 (de) * 2002-09-20 2008-11-12 M7 Visual Intelligence Lp Fahrzeuggest tzte datensammlung und verarebitungssystem
ATE541840T1 (de) 2002-09-30 2012-02-15 Gea Farmaceutisk Fabrik As Raloxifene-l-lactat oder ein hemihydrat davon, deren verwendungen, pharmazeutischen zusammensetzungen und herstellungsverfahren
AU2003290816A1 (en) 2002-11-12 2004-06-03 Pharmasset, Inc. Modified nucleosides as antiviral agents
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
EP1620110A2 (de) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Immunomodulatorische phosphonat konjugate
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096237A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
BRPI0409680A (pt) * 2003-04-25 2006-04-18 Gilead Sciences Inc análogos de fosfonato anti-cáncer
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1626950A4 (de) 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc Sertralinzusammensetzungen
CN101220070B (zh) 2003-06-16 2012-07-18 味之素株式会社 肌苷及其制造方法
NZ544988A (en) 2003-07-30 2009-11-27 Gilead Sciences Inc Nucleobase phosphonate analogs for antiviral treatment
JP5144930B2 (ja) 2003-08-18 2013-02-13 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジン
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
WO2005063258A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
US20050171126A1 (en) 2003-12-26 2005-08-04 Ajinomoto Co., Inc. Process for the production of purine nucleoside compounds
US7404949B2 (en) 2004-03-15 2008-07-29 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Methods and compositions useful to prevent in-grown hair arising from shaving
JP2008502609A (ja) 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US20060181714A1 (en) 2004-07-29 2006-08-17 Coherix, Inc Method for processing multiwavelength interferometric imaging data
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7154505B2 (en) 2004-11-11 2006-12-26 Stonecube Limited Method of and apparatus for generating a representation of an object
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US20080279932A1 (en) 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
WO2007075452A2 (en) 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
US20060223820A1 (en) 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
US20090163449A1 (en) 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
EP2305680A3 (de) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Neuartige Salze von (1S,4R)-cis-4-[2-amino-6-(cyclopropylamin)-9H-purin-9-yl]-2-cyclopenten-1-methanol
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
WO2014055603A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor

Also Published As

Publication number Publication date
WO2004096286A2 (en) 2004-11-11
EP1628685B1 (de) 2010-12-08
PT1628685E (pt) 2011-03-16
NO20055591D0 (no) 2005-11-25
JP2006524711A (ja) 2006-11-02
CA2523083C (en) 2014-07-08
JP2007238621A (ja) 2007-09-20
US20050215513A1 (en) 2005-09-29
AU2004233898A1 (en) 2004-11-11
US8871785B2 (en) 2014-10-28
EA200501680A1 (ru) 2006-04-28
US20090275535A1 (en) 2009-11-05
EA014685B1 (ru) 2010-12-30
NO20055591L (no) 2006-01-20
US8022083B2 (en) 2011-09-20
AU2004233898B2 (en) 2010-12-23
WO2004096286A3 (en) 2005-06-16
US9139604B2 (en) 2015-09-22
SG182849A1 (en) 2012-08-30
JP5069463B2 (ja) 2012-11-07
IL170894A (en) 2014-03-31
NZ542342A (en) 2009-05-31
CY1118836T1 (el) 2018-01-10
HK1085944A1 (en) 2006-09-08
US20150025039A1 (en) 2015-01-22
CA2523083A1 (en) 2004-11-11
EP1628685A2 (de) 2006-03-01
EP2359833A1 (de) 2011-08-24
US7429565B2 (en) 2008-09-30
NO338306B1 (no) 2016-08-08
US20130316969A1 (en) 2013-11-28
US20110288053A1 (en) 2011-11-24
MXPA05011297A (es) 2006-05-25
DK1628685T3 (da) 2011-03-21
PL1628685T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
ATE490788T1 (de) Antivirale phosphonate analoge
BRPI0409680A (pt) análogos de fosfonato anti-cáncer
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2005002626A3 (en) Therapeutic phosphonate compounds
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
CY1107301T1 (el) Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3
WO2004096285A3 (en) Anti-infective phosphonate conjugates
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
TW200738741A (en) Antiviral compounds
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2004096233A3 (en) Nucleoside phosphonate conjugates
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
WO2004096237A3 (en) Phosphonate analogs for treating metabolic diseases
MXPA05011289A (es) Compuestos de fosfato que tienen actividad inmunomoduladora.
UA92464C2 (en) Antiviral compounds
MXPA05011287A (es) Analogos de fosfonato anti-cancer.
BRPI0409766A (pt) análogos de fosfonato antiviral
BRPI0409679A (pt) compostos antiinflamatórios de fosfonato
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
UA96295C2 (en) Antiviral phosphinate compounds
BRPI0409691A (pt) compostos de fosfonato tendo atividade imuno-moduladora

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1628685

Country of ref document: EP